DalsnaFinance › Analyst accuracy › Benchmark › ABT target
Benchmark reiterates Buy on Abbott Labs stock, keeps $120 target
Investing.com - Benchmark reiterated a Buy rating and $120.00 price target on Abbott Laboratories (NYSE:ABT) following the company's second-quarter earnings report.
A fact about what Benchmark published, as reported by Investing.com, not a recommendation from Dalsna Finance; Benchmark is not affiliated with this site.
Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.